MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eclinm.2022.101323

Медицинская библиотека · EClinicalMedicine · 2022

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.

Pitisuttithum Punnee, Luvira Viravarn, Lawpoolsri Saranath, Muangnoicharoen Sant, Kamolratanakul Supitcha, Sivakorn Chaisith, Narakorn Piengthong, Surichan Somchaiya, Prangpratanporn Sumalee, Puksuriwong Suttida, Lamola Steven, Mercer Laina D, Raghunandan Rama, Sun Weina, Liu Yonghong, Carreño Juan Manuel, Scharf Rami, Phumratanaprapin Weerapong, Amanat Fatima, Gagnon Luc, Hsieh Ching-Lin, Kaweepornpoj Ruangchai, Khan Sarwat, Lal Manjari, McCroskery Stephen, McLellan Jason, Mena Ignacio, Meseck Marcia, Phonrat Benjaluck, Sabmee Yupa, Singchareon Ratsamikorn, Slamanig Stefan, Suthepakul Nava, Tcheou Johnstone, Thantamnu Narumon, Theerasurakarn Sompone, Tran Steven, Vilasmongkolchai Thanakrit, White Jessica A, Bhardwaj Nina, Garcia-Sastre Adolfo, Palese Peter, Krammer Florian, Poopipatpol Kittisak, Wirachwong Ponthip, Hjorth Richard, Innis Bruce L

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It's being developed by public sector manufacturers in Thailand, Vietnam, and Brazil; herein are initial results from Thailand.

METHODS

This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy males and non-pregnant females, aged 18-59 years and negative for SARS-CoV-2 antibodies, were eligible. Participants were randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 µg, 1 µg+CpG1018 (a toll-like receptor 9 agonist), 3 µg, 3 µg+CpG1018, 10 µg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov (NCT04764422).

FINDINGS: Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enroled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5·7% to 17·1% among vaccine groups and was 2·9% in controls; there was no vaccine-related serious adverse event. The 10 µg formulation's immunogenicity ranked best, followed by 3 µg+CpG1018, 3 µg, 1 µg+CpG1018, and 1 µg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122·23 international units per mL (IU/mL; 1 µg, 95% confidence interval (CI) 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to 100% of vaccine groups attaining a ≥ 4-fold increase over baseline.

INTERPRETATION: NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018 formulations advanced to phase 2.

FUNDING: National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, National Institutes of Health (USA).

Для цитирования: Pitisuttithum Punnee, Luvira Viravarn, Lawpoolsri Saranath, Muangnoicharoen Sant, Kamolratanakul Supitcha, Sivakorn Chaisith, Narakorn Piengthong, Surichan Somchaiya, Prangpratanporn Sumalee, Puksuriwong Suttida, Lamola Steven, Mercer Laina D, Raghunandan Rama, Sun Weina, Liu Yonghong, Carreño Juan Manuel, Scharf Rami, Phumratanaprapin Weerapong, Amanat Fatima, Gagnon Luc, Hsieh Ching-Lin, Kaweepornpoj Ruangchai, Khan Sarwat, Lal Manjari, McCroskery Stephen, McLellan Jason, Mena Ignacio, Meseck Marcia, Phonrat Benjaluck, Sabmee Yupa, Singchareon Ratsamikorn, Slamanig Stefan, Suthepakul Nava, Tcheou Johnstone, Thantamnu Narumon, Theerasurakarn Sompone, Tran Steven, Vilasmongkolchai Thanakrit, White Jessica A, Bhardwaj Nina, Garcia-Sastre Adolfo, Palese Peter, Krammer Florian, Poopipatpol Kittisak, Wirachwong Ponthip, Hjorth Richard, Innis Bruce L. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.. EClinicalMedicine. 2022. DOI: 10.1016/j.eclinm.2022.101323.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.